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Abstract
Background: Vaginal candidiasis is a frequent and common distressing disease affecting up to 75% of the women
of fertile age; most of these women have recurrent episodes. Essential oils from aromatic plants have been shown
to have antimicrobial and antifungal activities. This study was aimed at assessing the anti-fungal activity of essential
oil from Mentha suaveolens (EOMS) in an experimental infection of vaginal candidiasis.
Methods: The in vitro and in vivo activity of EOMS was assessed. The in vitro activity was evaluated under standard
CLSI methods, and the in vivo analysis was carried out by exploiting a novel, non-invasive model of vaginal
candidiasis in mice based on an in vivo imaging technique.
Differences between essential oil treated and saline treated mice were evaluated by the non-parametric Mann-
Whitney U-test. Viable count data from a time kill assay and yeast and hyphae survival test were compared using
the Student’s t-test (two-tailed).
Results: Our main findings were: i) EOMS shows potent candidastatic and candidacidal activity in an in vitro
experimental system; ii) EOMS gives a degree of protection against vaginal candidiasis in an in vivo experimental
system.
Conclusions: This study shows for the first time that the essential oil of a Moroccan plant Mentha suaveolens is
candidastatic and candidacidal in vitro, and has a degree of anticandidal activity in a model of vaginal infection, as
demonstrated in an in vivo monitoring imaging system. We conclude that our findings lay the ground for further,
more extensive investigations to identify the active EOMS component(s), promising in the therapeutically
problematic setting of chronic vaginal candidiasis in humans.
Background
Candida albicans is a major fungal pathogen of humans
[1,2] and a commensal organism of the gastrointestinal
tract. In severely immunocompromised patients this
fungus causes high morbidity and mortality. C. albicans
is also the etiological agent of vulvovaginal candidiasis, a
common pathological condition, afflicting normal
women of fertile age, which frequently develops into a
chronic, substantially incurable, disease [3].
Different classes of antimycotic drugs are available to
treat fungal infections. The azoles, particularly flucona-
zole, remain among the most common antifungal drugs,
but their intensive clinical use for both therapy and pro-
phylaxis has favoured the emergence of resistant strains
[4]. The phenomenon of drug resistance has raised
interest in substances of natural origin as a therapeutic
alternative. Essential oils (EO) of aromatic plants are
used by companies for the production of soaps, per-
fumes and toiletries. Many of them are also used in tra-
ditional medicine for various purposes [5-7]. In the last
years various EO have been found to show antimicro-
bial, antioxidant anticancer and other pharmacological
activities [8-10]. Particularly, a number of EO have been
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tested for in vivo and in vitro antimycotic activity and
some have been shown to be potential antifungal agents.
The EO have a complex composition based on a num-
ber of constituents with low molecular weight, and their
biological activities are due either to a main component
of the mixture, usually a monoterpene, or to the syner-
gic action of multiple compounds [11].
Mentha suaveolens has been used in the traditional
medicine of Mediterranean areas and has a wide range
of effects: tonic, stimulating, stomachic, carminative,
analgesic, choleretic, antispasmodic, sedative, hypoten-
sive and insecticidal. It shows depressor activity, analge-
sic and antiinflammatory action [12].
Mentha suaveolens plants collected in various regions
of Morocco contains a high percentage of oxides such as
piperitenone oxide (PEO) and piperitone oxide (PO), ter-
penic alcohol (fenohol, p-cymen-8-ol, geraniol, terpineol
and borneol) and terpenic ketones (pulegone and piperi-
tenone) all of which account for 65% to 90% of the total
essential oil. The antimicrobial activity of PO, even if
generally comparable to that of PEO, seems to be two-
fold lower than that of PEO against yeast [13]. No studies
have however addressed the in vivo activity of Mentha
suaveolens EO in a suitable experimental model of vagi-
nal candidiasis under controlled conditions. Thus, in this
study we have tested the in vitro and in vivo activity of
M. suaveolens EO against C. albicans. Particularly, for in
vivo activity, we used a recently developed, non-invasive
in vivo imaging technique, which exploits a novel cell
surface luciferase as reporter gene [14].
For both in vitro and in vivo studies, we used Jasmine




Mentha suaveolens essential oil was kindly provided by
the Department of Chemistry and Drug Technologies,
University of Rome “La Sapienza”, Italy. It was obtained
from wild-type plants grown in Tarquinia forests located
around 60 miles from Rome. The oil was extracted by
four-hour hydro distillation of the leaves using a Cleven-
ger-type apparatus as previously described [15], then ana-
lyzed for chemical composition by gas chromatography
and mass spectroscopy (DMePe BETA PS086, 0.25 mm
film on a 25 m column, diameter of 0.25 mm, operating
at 220°C and eluting with helium). Compounds were
identified by the application of the NIST 08 Mass Spec-
tral Library. Analysis revealed that piperitenone oxide
constitutes 90% of EOMS. Limonene and 1,8-cyneole
were also present, among other minor constituents.
Essential oils of tea tree (Melaleuca alternifolia)
(TTO) and jasmine oil (Jasminum grandiflorum) (JO)
also used in this research were commercial oils
purchased form Named (Lesmo, Italy) and Erboristeria
Magentina (Torino, Italy), respectively. They were
obtained by steam distillation from leaves and young
branches of tea tree, and from flowers of jasmine. TTO
is pure, extracted without additives and was used as a
positive control, because of documented antifungal
activity [16,17] while jasmine oil, which was shown to
be inactive against fungal growth, was used as a negative
control [18].
Fluconazole was obtained from Sigma-Aldrich
(Germany).
Microorganisms
Different strains of Candida albicans were used in the
study: four clinical isolates from AIDS patients AIDS68,
AIDS6, AIDS37 and AIDS126, CO23 isolated from a
subject with vulvo-vaginal candidiasis susceptible to
micafungin and fluconazole and the drug-resistant
strains CO23RFK (micafungin-resistant) and CO23RFLU
(fluconazole-resistant) [19], CA2, an echinocandin-resis-
tant, non-germinative strain that grows as a pure yeast
form at 28-37°C in conventional mycologic media [20],
GR5 isolated from a woman with recurrent vaginal can-
didiasis, 3153 intrinsically resistant to fluconazole,
ATCC10231 and ATCC24433. C. albicans CA1398 car-
rying the ACT1p-gLUC59 fusion (C. albicans gLUC59)
or C. albicans CA1398 that did not express gLUC59
(control strain) were used in the models of vaginal Can-
dida infections [14]. For experimental infections, cells
from stock cultures in YPD agar (1% yeast extract, 2%
peptone, 2% glucose, 1.5% agar, all w/v) with 50 μg/ml
chloramphenicol were grown in YPD broth (1% yeast
extract, 2% peptone,2% glucose, all w/v) at room tem-
perature for 24 h, then harvested by centrifugation,
washed, counted in an haemocytometer, and resus-
pended to the desired concentration in sterile physiolo-
gical saline. In order to examine the effect of the oil on
the mycelia form of Candida, yeasts were grown for 4 h
in RPMI 1640 plus 10% FBS at 37°C, then hyphae were
washed and incubated with different concentrations of
essential oils (EOMS, TTO and JO) for 24 h at 37°C.
Yeasts for infection were harvested from overnight cul-
tures in YPD agar plates and adjusted to the concentra-
tion 109/ml in sterile physiological saline.
Minimal Inhibitory Concentration (MIC) assay
The Minimal Inhibitory Concentration (MIC) was deter-
mined by micro-broth dilution method according to the
Clinical and Laboratory Standards Institute/National
Commitee for Clinical Laboratory Standards (CLSI/
NCCLS) Approved Standard M27-A3, 2008 [21]. Fluco-
nazole 0.5 g/L solution was prepared by dissolving the
agent in endotoxin free water. Solutions of essential oils
(100 g/L) were prepared in RPMI1640. Briefly, to
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determine the MIC of EOMS, TTO, JO or Fluconazole,
RPMI-1640 supplemented with MOPS at pH 7 was
used. EOMS, TTO and JO were diluted in RPMI-1640
supplemented with Tween 80 (final concentration of
0.001% v/v). The dilutions, ranging from 0.01219 to
12.48 g/L of the essential oils, were prepared in 96 well
plates. The inoculum size was about 2.5 × 103cells/ml.
The plates were incubated at 30°C for 24-48 h. To
determine the hyphae survival, C. albicans cells were
first grown for 4 h in RPMI supplemented with 10% of
FBS serum and then treated with different essential oils.
Minimal Fungicidal Concentration (MFC) assay
The Minimal Fungicidal Concentration (MFC) was
determined as the lowest concentration of Fluconazole
or essential oils at which no microbial growth was
observed. For the MFC determination, Sabouraud dex-
trose agar plates were seeded with 10 μl of cell suspen-
sions taken from the wells of the plates of MIC assay
where cell growth was not observed. These plates were
incubated at 30°C for 24-48 h and colony forming units
(CFU) growth was evaluated.
Time killing
To confirm the fungicidal activity of EOMS, time-kill pro-
cedures were performed as described by Klepser [22].
Cells sub-cultured in YPD at 28°C for 24 h were centri-
fuged, washed and resuspended at a concentration of 2.5 ×
105cell/ml in RPMI supplemented with EOMS or TTO
and incubated at 28°C. Essential oil concentrations used in
the test were equivalent to 1, 2, 4, and 8 times the MIC.
At predetermined time points (0, 0.5, 1, 2, 4, 6, 8, 24 and
48 hours) of incubation, 100 μl aliquots were removed
from the test solution and tenfold serial dilutions were
performed. 100 μl aliquot from each dilution was spread
on the surface of Sabouraud dextrose agar plates and incu-
bated at 37°C for 48 h for determination of CFU/ml.
Cell lines
Monomac-6, a human tumour cell line which was initi-
ally obtained from peripheral blood of a 60-year-old man
with acute monocytic leukaemia, and L929, a fibroblast-
like cell line cloned from strain L (the parent strain was
derived from normal subartaneous areolar and adipose
tissue of a male C3H/An mouse) were grown in a humi-
dified atmosphere containing 5% of CO2 at 37°C. The
culture medium consisted of RPMI 1640 with glutamine,
10% FBS (foetal bovine serum) and antibiotics. Every
three or four days the cultures were split.
Cytotoxicity assay
The cytotoxicity was tested by the determination of the
cell ATP level by ViaLight® Plus Kit (Lonza). The
method is based upon the bioluminescent measurement
of ATP that is present in all metabolically active cells.
The bioluminescent method utilizes an enzyme, lucifer-
ase, which catalyses the formation of light from ATP
and luciferin. The emitted light intensity is linearly
related to the ATP concentration and is measured using
a luminometer. To perform cytotoxicity tests, cells were
recovered and counted and adjusted to the concentra-
tion 106/ml. The examinations were carried out for
essential oils (EOMS, TTO and JO) and the control
(cells not treated). Various 1:2 dilutions of the above
mentioned oils were prepared in the medium (RMPI
1640, 10% FBS, antibiotics) in order to achieve final con-
centrations in the wells: 1000-500-250-125-62.5-31-16-
8-4-2-1-0 mg/L. Each concentration was tested in tripli-
cate. After adding oils into appropriate wells, cells were
added to each well to obtain the concentration of
105cells/well and incubated for 2 h at 37°C. Plates were
left in a room temperature to cool for 10 minutes and
then the Cell Lysis Reagent was added to each well to
extract ATP form the cells. Next, after 10 minutes the
AMR Plus (ATP Monitoring Reagent Plus) was added
and after 2 more minutes the luminescence was read
using a microplate luminometer (TECAN).
Mice
Female CD1 mice obtained from Harlan Italy Labora-
tories (Udine, Italy) were used at 4 to 6 weeks of age.
Mice were allowed to rest for 1 week before the experi-
ment; by that time the animals were roughly 5 to 7
weeks old. Animals were used under specific-pathogen-
free conditions that included testing sentinels for
unwanted infections; according to the Federation of Eur-
opean Laboratory Animal Science Association standards,
no infections were detected.
The experimental research was approved on 25 Janu-
ary 2008 by the Ethics Committee of the University of
Perugia.
Infection and treatment
Mice infection was performed as previously described
with minor adaptations [23]. Mice were maintained
under pseudoestrus condition by subcutaneous injection
of 0.2 mg of estradiol valerate in 100 μl of sesame oil
(Sigma-Aldrich) 6 days prior to infection and weekly
until the completion of the study. Mice anaesthetized
with 2.5-3.5 (v/v) isofluorane gas were infected twice at
a 24 h interval with 10 μl of 109 cell/ml of C. albicans
gLUC59 or the control strain. Cell suspensions were
administered from a mechanical pipette into the vaginal
lumen, close to the cervix. To favour vaginal contact
and adsorption of fungal cells, mice were held head
down for 1 min following inoculation. Mice were then
allowed to recover for 24-48 h, during which the Can-
dida infection was established.
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The intravaginal treatment with TTO, EOMS and JO
(500 μg/10 μl/mouse) was begun 2 h before the first
challenge and then it was repeated every two days until
day +21.
Monitoring of mouse vaginal infection
To monitor the infection during the treatment with
essential oil, every day post-infection (starting 48 h after
challenge) 10 μl (1 mg/ml in 1:4 methanol:H2O) of coe-
lenterazine was added to the vaginal lumen. Afterwards,
mice were imaged in the IVIS-200TM imaging system
under anaesthesia with 2.5% isoflurane. Total photon
emission from vaginal areas within the images (Region
Of Interest, ROI) of each mouse was quantified with
Living ImageR software package. In selected experiments
mice were anaesthetized with 2.5% isoflurane and then
held head down, the vaginal lumen was thoroughly
washed with 150 μl of saline. To determine the fungal
load in the vagina, 50 μl of the lavage fluids from each
mouse were plated on YPD agar plus chloramphenicol
(50 μg/ml), then CFUs were evaluated.
Statistical analysis
Differences between essential oil treated and saline trea-
ted mice were evaluated by the non-parametric Mann-
Whitney U-test. Viable count data from time kill assay
and yeast and hyphae survival test were compared using
the Student’s t-test (two-tailed). P-values of < 0.05 were
considered significant.
Results
MIC, MFC and Killing Kinetics
The initial determination of the antifungal activity of
essential oils (EOMS, TTO and JO) was performed in
vitro by standardized CLSI/NCCLS methods[21] and
this was done against all strains of C. albicans used
throughout this study. MIC values fell in a range of
0.39-0.78 g/L for EOMS and 0.78-3.12 g/L for TTO.
The MFC values ranged from 0.39-1.56 g/L for EOMS
and 1.56-6.24 for TTO, thus very close to MIC values.
In our experimental system, TTO was less efficient than
EOMS especially when the oils were tested against flu-
conazole resistant strains. In addition MFC values for
TTO were higher than EOMS for all strains tested
(table 1). JO, used as a negative control, did not affect
the growth of any strain tested.
To obtain more insight into the anticandidal activity of
EOMS on gLUC59, i.e the strain used in the experimen-
tal vaginal infection (see below), a time-kill test at con-
centrations equivalent to 1, 2, 4, and 8 times of the MIC
value (0.39 g/L) was performed. As reported in Figure 1,
at a concentration of 2 × MIC (0.78 g/L), the number of
colonies was significantly reduced after 24 hrs of incuba-
tion (P < 0.05) and the total fungicidal effect was
observed within 48 hrs of contact. The results demon-
strated that C. albicans gLUC59 was highly susceptible to
EOMS. In parallel we analyzed the time kill test for TTO,
confirming that this oil exerted a fungicidal effect within
48 hrs at a concentration higher (3,12 g/L; P < 0.05) than
that observed with the EOMS (0,78 g/L).
Yeasts and the mycelial form have different
susceptibilities to EOMS
Given that EOMS affects C. albicans yeast forms of
growth, we extended our investigations to the virulent
mycelial form of C. albicans. To this end C. albicans
was cultured at 37°C for 4 h in the presence of 10% of
FBS serum. Microscopic examination demonstrated
Table 1 Antifungal activity of EOMS, TTO, JO and fluconazole on different Candida albicans strains
EOMS TTO JO Fluconazole
Strains MIC g/L MFC g/L MIC g/L MFC g/L MIC g/L MFC g/L MIC mg/L MFC mg/L
AIDS68 0.39 0.78 3.12 3.12 > 100 > 100 > 64 > 128
AIDS6 0.39 0.78 3.12 6.24 > 100 > 100 > 64 > 128
AIDS37 0.39 0.39 3.12 6.24 > 100 > 100 > 64 > 128
AIDS126 0.39 0.78 3.12 6.24 > 100 > 100 0,25 2
CA2 0.39 0.39 3.12 6.24 > 100 > 100 0,5 > 128
GR5 0.39 0.78 3.12 3.12 > 100 > 100 2 > 128
3153 0.39 0.78 3.12 6.24 > 100 > 100 64 > 128
CO23 0.39 0.39 0.78 1.56 > 100 > 100 0.25 1
CO23RFK 0.78 1.56 0.78 1.56 > 100 > 100 0.25 1
CO23RFLU 0.78 1.56 0.78 3.12 > 100 > 100 > 64 > 128
ATCC10231 0.39 0.39 3.12 6.24 > 100 > 100 4 4
ATCC24433 0.39 0.39 3.12 6.24 > 100 > 100 0.25 1
gLUC59 0.39 1.56 3.12 6.24 > 100 > 100 0.39 0.78
gLUC59 Control strain 0.39 1.56 3.12 6.24 > 100 > 100 0.39 0.78
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>90% mycelial conversion under our conditions. As
shown in Figure 2, hyphal forms were less susceptible to
EOMS than yeast forms, since inhibition of hyphal
growth is obtained at a significantly higher concentra-
tion (0.098 g/L) than the concentration required to inhi-
bit yeast forms of growth. In fact, a concentration of 0.5
g/L was able to completely inhibit the yeast cells but
not the hyphal form (Figure 2A-B) Notably, the EOMS
showed a greater inhibitory effect than TTO, in both
yeast cells (0.05 vs 0.098 g/L respectively) and the
hyphal form (0.098 vs 0.39 g/L respectively). Jasmine Oil
did not affect the viability of yeast or mycelial cells. The
lack of effect of EOMS 0.5 g/L on hyphal survival was
documented by microscopic examination of hyphal
damage observed after addition of EOMS (Figure 2C).
Experiments were also performed to examine whether
the EOMS expressed cytotoxicity towards immune cells.
To this end, Monomac 6 and L929 cell lines were trea-
ted with various concentrations of EOMS for 2 and 24
h. The results reported in Figure 3 show that high con-
centrations of EOMS (0.5 and 1 g/L), i.e. higher than
the MIC value, were necessary to exert cytotoxicity on
Monomac 6 and L929 cell lines. Using the same con-
centrations a similar trend was observed for TTO, while
no cytotoxicity resulted from JO treatment.
Effect of EOMS on vaginal candidiasis
Given the encouraging results observed in vitro, we
wondered whether these beneficial effects against C.
albicans could be reproduced in an in vivo system. To
this purpose we exploited the new in vivo imaging tech-
nique which we have recently developed in our labora-
tory [14,24] to assess therapeutic efficacy in an
estrogen-dependent mouse model of vaginal candidiasis.
Estradiol treated mice were infected with C. albicans
expressing luciferase gene gLUC and EOMS, TTO or JO
were administered intravaginally 2 h before the first chal-
lenge and then every two days. The course of the infection
was monitored at various days post challenge by in vivo
imaging (Figure 4). The fungal load in the vagina was
quantified as photon emission as well as CFU from vaginal
fluids. The results reported in Figure 5 show that there is a
significant reduction of Candida load in mice treated with
EOMS with respect to diluent (saline) treated mice start-
ing from 15 days post infection, and this beneficial effect
was maintained until 21 days post infection. In this model,
and under the conditions tested, TTO was only minimally
effective in causing a significant reduction of vaginal fun-
gus load, measured as photon emission at 9 and 15 days.
No effect was recorded after 21 days of infection.
Discussion
Human pathogenic fungi represent a significant propor-
tion of the infectious agents affecting the immunocom-
promised host. The therapeutic options for these
patients are hampered by i) the relative scarcity of active
and safe antifungal drugs, most of which are essentially
fungistatic rather than fungicidal, ii) antifungal drug
resistance to the most active and widely used azole com-
pounds, iii) the difficulties of devising and/or constantly
Figure 1 Time kill curve of EOMS and TTO against Candida
albicans gLUC59. Cells were untreated (control) or treated with
0.39, 0.78, 1.56, or 3.12 g/L of EOMS or treated with 3.12, 6.25, 12.5
or 25 g/L of TTO for different time periods (0, 0.5, 1, 2, 4, 6, 8, 24
and 48 hours). After incubation survival cells were determined by
cultivation on Sabouraud dextrose agar plates at 37°C for 48 h.
Results are expressed as CFU/ml and indicated as mean ± SEM of
triplicate samples. Data are representative of one of three
independent experiments. The statistical significance was evaluated
with the Student’s t-test (two-tailed). *P-values of < 0.05 were
considered significant.
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maintaining effective infection control measures in the
health care institutions. Overall, fungal infections in
immunodepressed subjects are a very challenging pro-
blem for the health system.
Thus there is a clear demand for finding a new thera-
peutic approach in this era of increasing spreading of
antimicrobial drug resistance and re-emergence of infec-
tious diseases [25,26].
Recently the use of TTO as a new approach in antifun-
gal therapy has been proposed. This natural compound
appears to be effective in vitro against multidrug resistant
Candida and in vivo against mucosal candidiasis [27].
Figure 2 Effect of essential oil on yeast and hyphae survival. gLUC59 Candida albicans yeast cells (A) and preformed hyphae (B) were
treated with different concentrations of essential oils (EOMS, TTO and JO) for 24 h. After incubation 10 μl of coelenterazine substrate (1 mg/ml)
was added to each well and samples were read using a luminometer. Results are expressed as percentage of yeast or hyphae survival and
indicated as mean ± SD of triplicate samples are from one of three experiments with similar results. The statistical significance was evaluated
with the Student’s t-test (two-tailed). *P-values of < 0.05 were considered significant. The effect on preformed hyphae was microscopically
examined after 24 h of treatment with essential oil (C). Original magnification of 20x or 40x is indicated in the micrographs. The results are
representative of one of three independent experiments.
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Moreover it has also been documented that terpinen-4-ol
rather than 1,8-cineole is the most likely mediator of TTO
activity or, at least, a main contributor to anti-Candida
activity [16]. In this study we used TTO as a positive con-
trol in our in vitro and in vivo experimental system.
Regarding the antimicrobial properties of EOMS
recent evidence attributes larvicidal activity to this
essential oil and its active compound [28]. Other impor-
tant activities of EOMS include protective effects against
hydrogen-peroxide-induced-cytotoxicity. Anti-Candida
activity has been described for Mentha piperita [29].
Furthermore EOMS was effective against Gram positive
and Gram negative microorganisms and fungi [13]. The
main microbicidal components of EOMS were pulegone
and piperitone oxide.
In this study we demonstrated for the first time that
EOMS is endowed with potent anticandidal activity in
vitro, both against azole-susceptible and azole-resistant
Candida strains. In addition, EOMS was shown to be
not only an inhibitor of Candida growth, but also able
to actually kill the yeasts. We determined the time kill-
ing curves, and so discovered that EOMS was apparently
more effective than the more extensively investigated
TTO. All experiments were performed against a control,
the jasmine oil, which proved totally ineffective.
The antifungal activity is manifested against both yeast
and the mycelial form, although higher EOMS concentra-
tions were required to kill these latter forms of growth.
Finally, we provide evidence that intravaginal administra-
tion of EOMS in vivo is also efficacious to some degree.
Figure 3 Cytotoxicity of essential oils on mammalian cells. Monomac 6 and L929 cells were treated with different concentrations of
essential oils for 2 h. The cytotoxicity was tested by the determination of the cell ATP level by a bioluminescent method. Results, expressed as
Relative luciferase activity (RLUC), represent the mean ± SD of three different experiments. The statistical significance was evaluated with the
Student’s t-test (two-tailed). *P-values of < 0.05 were considered significant.
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For the in vivo assay, a stringent and controlled model
of vaginal infection of mice was used. This exploits a
novel cell surface luciferase as reporter gene, con-
structed by fusing a synthetic, codon-optimized version
of the Gaussia princeps luciferase gene to Candida albi-
cans PGA59, which encodes a glycosylphosphatidyl ino-
sitol-linked cell wall protein [14]. This technique allows
a continuous, non invasive monitoring of the spatial and
temporal progression of vaginal infection in a small
number of live mice. The model proved useful in assay-
ing for anticandidal protection in actively or passively
immunized animals [24]. The method was paralleled by
a more traditional determination of vaginal fungus load
in the vagina by CFU. The in vivo imaging technique
resulted much more sensitive than the classic CFU
method for at least two different reasons: 1) the vaginal
wash doesn’t completely clear the vaginal lumen because
the Candida hyphae are well attached to the tissue; 2)
several hyphae often grew as a single colony, causing an
underestimation of the fungal load.
Overall, we show here that EOMS accelerates the
clearance of fungus during vaginal candidiasis, and this
Figure 4 In vivo imaging of mice vaginally infected with Candida albicans and treated with essential oils. The vaginal lumen of mice
under pseudoestrus condition were infected for 2 consecutive days with 10 μl of a 109 cell/ml suspension of Candida albicans gLUC59 (first
three mice of each group) or control strain (fourth mouse of each group) and treated with the different essential oils 2 h before the first
challenge and then every two days. After 5, 7, 9, 15 and 21 days post-infection mice were treated intravaginally with 10 μg of coelenterazine
and imaged in the IVIS-200TM imaging system under anaesthesia with 2.5% isoflurane. Total photon emission from vaginal areas within the
images (Region Of Interest, ROI) of each mouse was quantified with Living ImageR software package. Data are from one of three experiments
with similar results.
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accelerated clearance of Candida is demonstrated by
both photon emission and CFU measurements. The
EOMS activity in our model seems superior, at least
after 21 days of infection, to that of TTO, which has
previously been found particularly efficacious in a rat
model of vaginal candidiasis [16].
Our data are potentially relevant in the treatment of
Candida vulvovaginal infection (VVC). This is a frequent
and commonly distressing disease affecting 70-75% of
childbearing age women worldwide at least once during
their lives. Predisposing factors for developing an acute
form of vaginal candidiasis include antibiotic and oral
contraceptive usage, hormone replacement therapy,
pregnancy, uncontrolled diabetes mellitus and African
American ethnicity [30,31]. 5% and possibly up to 10% of
women with a primary episode subsequently experience
frustrating recurrent VVC (RVVC) which is defined as at
least three-four specific episodes within one year [3,32].
Conclusions
This study shows for the first time that: i) EOMS has
considerable in vitro, candidastatic and candidacidal
activity ii) EOMS administration in vivo accelerates the
clearance of C. albicans during vaginal infection.
The high impact of this infection and the difficulty of
finding an effective therapy reinforces the need to search
for an alternative therapeutic approach to integrate or
even replace the current treatment. The present results
could provide the ground for further investigations, par-
ticularly aimed at identifying the therapeutically active
anticandidal EOMS component(s).
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